GamaMabs Pharma is a clinical-stage immuno-oncology company developing optimized therapeutic antibodies for the treatment of cancer.

generique du cialis 5mg
pharmacie belgique en ligne viagra
effets indésirables sildenafil
comment utiliser tadalafil
comment acheter cialis

GamaMabs’ lead project is the monoclonal antibody (mAb) GM102 which targets Anti-Müllerian Human Receptor II (AMHRII), an unaddressed specific target in gynecological cancers.

The company develops low-fucose EMABling® antibodies with increased tumor cell killing properties through the activation of immune system cells.